Could a cancer drug fix a bleeding disorder and prevent leukemia?
NCT ID NCT06090669
First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 12 times
Summary
This early-stage trial tests imatinib, a drug already used for certain cancers, in adults with a harmful RUNX1 gene mutation. The mutation causes easy bleeding and a high risk of blood cancers. The study aims to find the best dose and see if imatinib can improve platelet function and reduce inflammation. Participants take imatinib daily for up to 84 days, with regular blood tests and optional bone marrow biopsies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- imatinib
- What this could lead to
- If it works, this could point toward a treatment that lowers bleeding risk and possibly delays blood cancers in people with RUNX1 deficiency.
- What could go wrong
- This is a very early Phase 1 trial with only 75 participants, so safety and effectiveness are not yet known. Imatinib may not improve platelet function or reduce cancer risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PLATELET DISORDER WITH PREDISPOSITION TO MYELOID MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.